Compare Stocks: ATNM, ELDN, WHWK, and DTIL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.42 +1.4%	$1.17	$0.74 ▼ $1.72	$44.02M	0.26	156,490 shs	106,852 shs
DTIL Precision BioSciences	$6.79 +5.9%	$6.97	$3.53 ▼ $9.62	N/A	N/A	N/A	164,247 shs
ELDN Eledon Pharmaceuticals	$2.41 +9.0%	$2.73	$1.35 ▼ $4.60	N/A	N/A	N/A	935,234 shs
WHWK Whitehawk Therapeutics	$3.33 +6.1%	$3.95	$1.97 ▼ $5.49	N/A	N/A	N/A	290,060 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	-7.89%	+6.06%	+16.67%	+61.57%	-16.17%
DTIL Precision BioSciences	-3.46%	+3.55%	+3.05%	-10.60%	-4.61%
ELDN Eledon Pharmaceuticals	-3.91%	+2.31%	-16.60%	-35.00%	-36.49%
WHWK Whitehawk Therapeutics	-2.18%	+4.32%	-16.04%	-14.67%	+30.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.42 +1.4%	$1.17	$0.74 ▼ $1.72	$44.02M	0.26	156,490 shs	106,852 shs
DTIL Precision BioSciences	$6.79 +5.9%	$6.97	$3.53 ▼ $9.62	N/A	N/A	N/A	164,247 shs
ELDN Eledon Pharmaceuticals	$2.41 +9.0%	$2.73	$1.35 ▼ $4.60	N/A	N/A	N/A	935,234 shs
WHWK Whitehawk Therapeutics	$3.33 +6.1%	$3.95	$1.97 ▼ $5.49	N/A	N/A	N/A	290,060 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	-7.89%	+6.06%	+16.67%	+61.57%	-16.17%
DTIL Precision BioSciences	-3.46%	+3.55%	+3.05%	-10.60%	-4.61%
ELDN Eledon Pharmaceuticals	-3.91%	+2.31%	-16.60%	-35.00%	-36.49%
WHWK Whitehawk Therapeutics	-2.18%	+4.32%	-16.04%	-14.67%	+30.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNM Actinium Pharmaceuticals	3.00	Buy	$5.00	252.11% Upside
DTIL Precision BioSciences	2.60	Moderate Buy	$32.25	374.96% Upside
ELDN Eledon Pharmaceuticals	2.33	Hold	$10.00	314.94% Upside
WHWK Whitehawk Therapeutics	2.75	Moderate Buy	$8.33	150.25% Upside

Current Analyst Ratings Breakdown

Latest ATNM, ELDN, WHWK, and DTIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	WHWK Whitehawk Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$9.00
9/21/2026	ELDN Eledon Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/2/2026	WHWK Whitehawk Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
8/5/2026	DTIL Precision BioSciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
8/3/2026	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy

(Data available from 10/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNM Actinium Pharmaceuticals	$35.09M	1.27	N/A	N/A	$1.31 per share	1.08
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNM Actinium Pharmaceuticals	-$48.82M	$0.36	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
DTIL Precision BioSciences	N/A	-$2.80	N/A	N/A	N/A	N/A	N/A	N/A	11/2/2026 (Estimated)
ELDN Eledon Pharmaceuticals	N/A	-$0.91	N/A	N/A	N/A	N/A	N/A	N/A	11/13/2026 (Estimated)
WHWK Whitehawk Therapeutics	N/A	-$1.12	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ATNM, ELDN, WHWK, and DTIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	Q3 2026	ELDN Eledon Pharmaceuticals	-$0.20	N/A	N/A	N/A	N/A	N/A
11/2/2026	Q3 2026	DTIL Precision BioSciences	-$0.85	N/A	N/A	N/A	$1.38 million	N/A
8/13/2026	Q2 2026	ELDN Eledon Pharmaceuticals	-$0.1580	-$0.27	-$0.1120	-$0.27	N/A	N/A
8/6/2026	Q2 2026	DTIL Precision BioSciences	-$0.8040	-$1.26	-$0.4560	-$1.26	$0.74 million	N/A
8/6/2026	Q2 2026	WHWK Whitehawk Therapeutics	-$0.30	-$0.20	+$0.10	-$0.20	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
DTIL Precision BioSciences	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNM Actinium Pharmaceuticals	27.50%
DTIL Precision BioSciences	37.99%
ELDN Eledon Pharmaceuticals	56.77%
WHWK Whitehawk Therapeutics	52.08%

Insider Ownership

Company	Insider Ownership
ATNM Actinium Pharmaceuticals	0.91%
DTIL Precision BioSciences	2.70%
ELDN Eledon Pharmaceuticals	9.60%
WHWK Whitehawk Therapeutics	49.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNM Actinium Pharmaceuticals	25	31.44 million	29.32 million	Optionable
DTIL Precision BioSciences	67	N/A	26.86 million	Optionable
ELDN Eledon Pharmaceuticals	33	N/A	73.46 million	Optionable
WHWK Whitehawk Therapeutics	23	N/A	28.56 million	Optionable

ATNM, ELDN, WHWK, and DTIL Headlines

Recent News About These Companies

Whitehawk Therapeutics (NASDAQ:WHWK) versus BeyondSpring (NASDAQ:BYSI) Financial Analysis

October 21, 2026 | americanbankingnews.com

Biogen (NASDAQ:BIIB) and Whitehawk Therapeutics (NASDAQ:WHWK) Head to Head Survey

October 16, 2026 | americanbankingnews.com

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Stock Has Consensus Target Price of $8.33 According to Brokerages

October 8, 2026 | marketbeat.com

Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 As A Durable ADC Target In Ovarian Cancer And Reinforces Scientific Rationale For HWK-016

October 3, 2026 | marketscreener.comM

Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026

October 1, 2026 | prnewswire.com

Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Whitehawk Therapeutics: PTK7 Stability Supports ADC Development In EGFR Wild-Type NSCLC

September 14, 2026 | rttnews.com

Whitehawk data support PTK7 target for HWK-007

September 14, 2026 | grafa.comG

Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026

September 13, 2026 | prnewswire.com

Whitehawk Therapeutics Adds Oncology Leader to Board

September 10, 2026 | tipranks.com

Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors

September 10, 2026 | prnewswire.com

Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

September 2, 2026 | prnewswire.com

What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?

August 28, 2026 | zacks.com

Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know

August 26, 2026 | zacks.com

Whitehawk Therapeutics Inc WHWK

August 14, 2026 | morningstar.comM

TD Cowen Remains a Hold on Whitehawk Therapeutics (WHWK)

August 10, 2026 | theglobeandmail.com

Whitehawk’s HWK-016 ADC Trial Advances in Tough Ovarian and Endometrial Cancers

August 6, 2026 | tipranks.com

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

August 6, 2026 | prnewswire.com

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

July 7, 2026 | businesswire.com

10 Hot Biotech Stocks Under $5 to Buy

June 10, 2026 | insidermonkey.com

Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?

June 10, 2026 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM, ELDN, WHWK, and DTIL Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

$1.42 +0.02 (+1.43%)

Closing price 04:00 PM Eastern

Extended Trading

$1.46 +0.04 (+2.68%)

As of 07:56 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Precision BioSciences NASDAQ:DTIL

$6.79 +0.38 (+5.93%)

Closing price 04:00 PM Eastern

Extended Trading

$6.79 0.00 (0.00%)

As of 07:30 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Eledon Pharmaceuticals NASDAQ:ELDN

$2.41 +0.20 (+9.05%)

Closing price 04:00 PM Eastern

Extended Trading

$2.42 +0.01 (+0.25%)

As of 07:30 PM Eastern

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Whitehawk Therapeutics NASDAQ:WHWK

$3.33 +0.19 (+6.05%)

Closing price 04:00 PM Eastern

Extended Trading

$3.32 0.00 (-0.15%)

As of 04:30 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATNM, ELDN, WHWK, and DTIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATNM, ELDN, WHWK, and DTIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATNM, ELDN, WHWK, and DTIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM, ELDN, WHWK, and DTIL Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

Precision BioSciences NASDAQ:DTIL

Eledon Pharmaceuticals NASDAQ:ELDN

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATNM, ELDN, WHWK, and DTIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATNM, ELDN, WHWK, and DTIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATNM, ELDN, WHWK, and DTIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM, ELDN, WHWK, and DTIL Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

Precision BioSciences NASDAQ:DTIL

Eledon Pharmaceuticals NASDAQ:ELDN

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools